Melodiol says subsidiary Halucenex reports remission in 80 percent of first five patients in tri

Latest News

Melodiol Global Health (ASX:ME1) has announced that its wholly-owned psychedelics subsidiary, Halucenex Life Sciences, has achieved encouraging preliminary results in the first five patients taking part in the phase 2 clinical trial exploring the use of psilocybin in the treatment of Post Traumatic Stress Disorder (‘PTSD’).

The trial, which commenced in December 2022, is a single-arm, open-label trial to test the efficacy of psilocybin on treatment-resistant PTSD symptoms. The trial utilises Halucenex’s synthetic psilocybin aqueous solution Lucenex, in both 10mg and 25mg formats, which is being delivered to 20 patients on separate occasions in a micro dose and macro dose format.

The company said that initial results show that 80 per cent of participants have achieved remission from treatment-resistant PTSD following two doses of psilocybin. 

CEO and managing director William Lay said, “Results from the first five patients that have undergone psilocybin dosage, using our unique Lucenex solution are nothing short of exceptional. A remission rate of 80 per cent by day 44 of treatment provides considerable validation of Halucenex’s approach and potential as a viable treatment option for patients suffering from treatment-resistant PTSD symptoms."